Co-model for chemical toxicity prediction based on multi-task deep learning.

The toxicity of compounds is closely related to the effectiveness and safety of drug development, and accurately predicting the toxicity of compounds is one of the most challenging tasks in medicinal chemistry and pharmacology. In this paper, we construct three types of models for single and multi-tasking based on 2D and 3D descriptors, fingerprints and molecular graphs, and then validate the models with benchmark tests on the Tox21 data challenge. We found that due to the information sharing mechanism of multi-task learning, it could address the imbalance problem of the Tox21 data sets to some extent, and the prediction performance of the multi-task was significantly improved compared with the single task in general. Given the complement of the different molecular representations and modeling algorithms, we attempted to integrate them into a robust Co-Model. Our Co-Model performs well in various evaluation metrics on the test set and also achieves significant performance improvement compared to other models in the literature, which clearly demonstrates its superior predictive power and robustness.

Acyclovir or Aß42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells.

Human brains harbor herpes simplex virus type-1 (HSV-1) DNA, which normally remains quiescent throughout many decades of life. HSV-1 is associated with viral encephalopathy and with the amyloid beta 42 (Abeta42) peptide-enriched lesions that characterize Alzheimer's disease neuropathology. Here we report that infection of human neuronal-glial cells in primary co-culture with HSV-1 induces an irregular hypertrophy of human neuronal-glial cell bodies, an induction of HSV-1 DNA polymerase, and an up-regulation of micro-RNA-146a associated with altered innate-immune responses. Presence of the antiviral acyclovir or soluble Abeta42 peptide significantly attenuated these neuropathological responses. The inhibitory effects of Abeta42 peptide were also observed in an HSV-1-infected CV-1 cell-based viral plaque assay. The results suggest that soluble Abeta42 peptide can invoke non-pathological and anti-viral effects through inactivation of an HSV-1 challenge to human brain cells by simple viral sequestration, viral destruction, or by complex neurogenetic mechanisms.